Clinical remission is achievable in patients with moderate to severe asthma treated with inhaled therapy only, according to results presented at the American Academy of Allergy, Asthma & Immunology annual meeting held from February 23 to 26, 2024 in Washington, DC.
To determine whether asthma clinical remission (CR) could be attained with just inhaled therapy, researchers conducted a post hoc analysis of the phase 3 CAPTAIN trial (ClinicalTrials.gov Identifier: NCT02924688), which compared treatment with fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) to fluticasone furoate and vilanterol (FF/VI) in adults with inadequately controlled asthma despite treatment with an inhaled corticosteroid/long-acting β2-adrenergic agonist.
“CR was defined as no systemic corticosteroid use, no severe exacerbations, ACQ-5 total score ≤1.5, and change from baseline in trough FEV1 ≥100mL,” the researchers explained. Assessments for CR were made at weeks 24 and 52 for the following dosages: FF/UMEC/VI 100/62.5/25mcg (n=406) or 200/62.5/25mcg (n=408) vs FF/VI 100/25mcg (n=407) or 200/25mcg (n=406).
Results at week 24 showed 31% and 36% of patients treated with FF/UMEC/VI 100/62.5/25mcg or 200/62.5/25mcg achieved CR compared with 19% and 26% receiving FF/VI 100/25mcg or 200/25mcg. At week 52, CR was achieved by 30% and 38% of patients treated with FF/UMEC/VI 100/62.5/25mcg or 200/62.5/25mcg vs 21% and 24% receiving FF/VI 100/25mcg or 200/25mcg.
At week 24, a comparison of dosage showed that CR achievement was more likely with FF/UMEC/VI 100/62.5/25mcg vs FF/VI 100/25mcg (odds ratio [OR], 1.93 [95% CI, 1.39-2.68], P <.001; risk ratio [RR], 1.65 [95% CI, 1.29-2.12], P <.001). Similar results were seen when FF/UMEC/VI 200/62.5/25mcg was compared with FF/VI 200/25mcg (OR, 1.62 [95% CI, 1.19-2.19], P =.002; RR, 1.40 [95% CI, 1.13-1.72], P =.002).
Based on these findings the authors concluded that a greater proportion of patients achieved CR with the single inhaler triple therapy, adding that “CR is a feasible treatment goal for patients with moderate to severe asthma receiving FF/UMEC/VI and FF/VI.”
Disclosure: Some of the study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
This article originally appeared on MPR.
